Dr. Matthew Halpert, instructor of immunology at Baylor College of Medicine, has spent the past year studying and researching the different ways in which CBD interacts with the body: “It’s become very evident that CBD can, in fact, interact with the body in a variety of ways, and exert several different health benefits. It is certainly worth it to study CBD and these other cannabinoids and how they may be very helpful.” Because regulating cellular homeostasis is beneficial for controlling cancer growth and tumor development, CBD became a subject of interest for Halpert and his team. Halpert is confident that, eventually, doctors will be prescribing CBD to patients and that CBD will be reimbursable by health insurance plans.
Seth Adler: Dr. Matthew Halpert joins us. Welcome to Cannabis Economy, I'm your host, Seth Adler. Download episodes on CanEconnomy.com, that's two Ns in the word economy, or wherever you currently get your podcasts. First a word from our support, and then Dr. Matthew Halpert.
Speaker 2: Bedrocan is a patient driven, global pharmaceutical minded cannabis company. Their entire end to end process is GMP certified through Dutch and ultimately European authorities. Bedrocan is the market leader in Europe for medical cannabis, and has been the sole supplier to the Dutch government for 16 years. Through the Dutch government, Bedrocan provides product to 15 countries currently. As a science based company, Bedrocan invests in clinical research. The Leiden University conducted a double blind placebo controlled clinical trial on fibromyalgia with Bedrocan products, which yielded promising results. They are now working on a followup to that study.
Speaker 2: Bedrocan is also working on the extent to which cannabis can reduce our reliability on opioids. Bedrocan believes that clinical research is key for the future of the company, standardized product, the industry, and the patient. Visit Bedrocan.com for more information.
Seth Adler: Okay, we've got Dr. Matt Halpert. Dr. Halpert, thank you for doing this, appreciate your time.
Dr. Halpert: Yes, thank you for having me.
Seth Adler: So you're one of these people, one of these learned people that actually has been doing work with cannabis.
Dr. Halpert: Yes. I would-
Seth Adler: You've been studying the plant.
Dr. Halpert: I have been studying it, yes, I'm learned about the plant, yes.
Seth Adler: All right, so where did the plant and you intersect? What was the timeframe and how come?
Dr. Halpert: So I've been working with CBD for a little over a year now, in regards to academic research here at Baylor College of Medicine in my lab. And over the past couple of years, as the CBD industry has grown, both in terms of a consumer base as well as our knowledge base, there's been an increase in academic research, and it's become very evident that CBD can, in fact, interact with the body in a variety of ways, and exert several different health benefits. And so it is certainly worth it to study CBD and these other cannabinoids and how they may be very helpful.
Dr. Halpert: So I started working on that about a year and a half ago.
Seth Adler: What were you working on just before that so we understand how you came into it?
Dr. Halpert: So just before that, as well as onto the side of that, I've been working with the ... studying the immune system, specifically in regards to cancer, cancer therapy, and how we can come up with vaccines and treatments that might help the body be able to fight off cancer and be much healthier.
Become a member to access to webinars, quarterly reports, contributor columns, shows, excerpts, and complete podcast transcripts